MSCOVID and natalizumab

M

As we have reported last week people taking natlaizumab and pfizer generally seroconvert. So another first first

Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, d’Ambrosio A, Matrone F, Risi M, Borgo RM, Altieri M, Giuliano F, Coppola N, Galdiero M, Tedeschi G, Gallo A. Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab. Ther Adv Neurol Disord. 2021 Aug 13;14:17562864211038111.

No correlations were found between IgG titers measured 7 days after the second vaccine dose and (1) age, (2) disease duration, (3) body mass index (BMI), (4) EDSS, (5) treatment duration, and (6) days elapsed since last NTZ administration. No differences were found in IgG titers (p = 0.59) between pwMS on standard interval dose (every 4 weeks: 10 pwMS) and those on extended interval dose (every 6 weeks: 16 pwMS).

We observed an efficient short-term humoral response to BNT162b2 mRNA Covid-19 vaccine in pwMS treated with NTZ. These results are in line with studies showing an efficient humoral immune response to influenza and tetanus toxoid vaccines in pwMS on NTZ. 

About the author

MouseDoctor

6 comments

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives